Trastuzumab-Calicheamicin

Trastuzumab-Calicheamicin is an antibody-drug conjugate (ADC) of Anti-Her2 human monoclonal antibody Trastuzumab with Calicheamicin through a cleavable linker. Calicheamicin as toxicity payload in antibody-drug conjugates (ADCs) are effective therapeutics for leukemias with two recently approved in the United States: Mylotarg (gemtuzumab ozogamicin) targeting CD33 for acute myeloid leukemia and Besponsa (inotuzumab ozogamicin) targeting CD22 for acute lymphocytic leukemia. The DAR of Trastuzumab-Calicheamicin is 3.5 - 4.0. This product is used for research only. It can be used as a reference compound.

Product Details
Species Reactivity	Human
Host/Isotype	Cell culture/ IgG1
Class	Monoclonal
Type	Antibody-drug conjugate
Immunogen	Human Her2
DAR (Drug to Antibody Ratio)	3.5 - 4.0
Clone	Trastuzumab biosimilar
Conjugate	AcBut-Calicheamicin
Purity	>98%
Molecular Weight	~148kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	50 mM Sodium Phosphate, 0.05% Tween-20, pH7.4